worldwide offices | contact | help | sitemap
Diseases & products
Diseases & products home
About Novartis Vaccines
About Novartis Vaccines home
Novartis Vaccines history
Novartis Vaccines educational grants
Business development home
About the Business Development & Licensing group
Our areas of interest
Meningococcal Disease Press Kit
Seasonal Influenza Press Kit
Cultures & values
Diversity & inclusion
Safety and efficacy of Fluad vaccinations in Italy.
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million.
Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B.
Novartis begins shipment of seasonal influenza vaccines to US market for the 2014-2015 season.
Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero® to help protect US adolescents and young adults.
Vaccines US • Vaccines Germany • Vaccines Italy
See stock performance
Novartis Vaccines wins the Best Pharma Company award.
Novartis ranked no. 11 on Science's Top 20 Employers list.